Leap Therapeutics Inc LPTX

CAMBRIDGE, Mass., Sept. 5, 2023 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Douglas E. Onsi, President and Chief Executive Officer, will participate in two upcoming investor conferences:

Leap Presentation Details:

H.C. Wainwright 25^th Annual Global Investment Conference
Date: Monday, September 11^th, 2023
Time: 7:00 a.m. Eastern Time

Baird Global Healthcare Conference
Date: Wednesday, September 13^th, 2023
Time: 3:10 p.m. Eastern Time

A replay of the pre-recorded H.C. Wainwright presentation and a live webcast of the Baird fireside chat may be accessed on the Investors page of the company's website at https://investors.leaptx.com/, where a replay of the events will also be available for a limited time.

About Leap Therapeutics

Leap Therapeutics (Nasdaq: LPTX) is focused on developing targeted and immuno-oncology therapeutics. Leap's most advanced clinical candidate, DKN-01, is a humanized monoclonal antibody targeting the Dickkopf-1 (DKK1) protein. DKN-01 is being developed in patients with esophagogastric, gynecologic, and colorectal cancers. FL-301, is a humanized monoclonal antibody targeting Claudin18.2, being developed in patients with gastric and pancreatic cancer. Leap also has preclinical antibody programs targeting Claudin18.2/CD137 and GDF15. For more information about Leap Therapeutics, visit http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Leap Therapeutics, Inc.
617-714-0360
donsi@leaptx.com

Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
matthew@argotpartners.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-therapeutics-to-participate-at-upcoming-investor-conferences-301917374.html

SOURCE Leap Therapeutics, Inc.